Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$44.45 +5.4%	$36.46	$21.72 ▼ $44.75	$8.01B	1.1	2.47 million shs	3.79 million shs
KYMR Kymera Therapeutics	$47.14 +1.8%	$35.90	$19.45 ▼ $53.27	$3.01B	2.07	613,053 shs	570,077 shs
LNTH Lantheus	$80.95 +0.2%	$85.93	$73.11 ▼ $126.89	$5.59B	0.11	1.01 million shs	943,124 shs
RVMD Revolution Medicines	$40.03 0.0%	$39.55	$29.17 ▼ $62.40	$7.46B	1.1	1.54 million shs	3.04 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+5.41%	+10.93%	+33.32%	+23.13%	+93.26%
KYMR Kymera Therapeutics	+1.84%	+1.70%	+59.85%	+55.12%	+49.89%
LNTH Lantheus	+0.17%	+3.89%	+9.60%	-17.76%	+2.53%
RVMD Revolution Medicines	-0.02%	+2.27%	+0.65%	+6.12%	+3.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5615 of 5 stars	4.5	2.0	3.9	1.8	3.3	0.6
KYMR Kymera Therapeutics	3.4869 of 5 stars	4.5	3.0	0.0	3.7	1.7	0.0
LNTH Lantheus	4.2303 of 5 stars	3.5	1.0	4.2	1.3	2.5	1.9
RVMD Revolution Medicines	4.2662 of 5 stars	4.5	1.0	4.7	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$56.67	27.48% Upside
KYMR Kymera Therapeutics	3.00	Buy	$59.82	26.91% Upside
LNTH Lantheus	3.00	Buy	$130.50	61.21% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	68.83% Upside

Current Analyst Ratings Breakdown

Latest KYMR, LNTH, RVMD, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00
6/2/2025	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$51.00
5/20/2025	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	38.04	N/A	N/A	($7.71) per share	-5.77
KYMR Kymera Therapeutics	$47.07M	65.22	N/A	N/A	$12.90 per share	3.65
LNTH Lantheus	$1.53B	3.65	$7.11 per share	11.39	$15.65 per share	5.17
RVMD Revolution Medicines	$11.58M	643.90	N/A	N/A	$13.47 per share	2.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	23.00	12.83	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest KYMR, LNTH, RVMD, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
KYMR Kymera Therapeutics	N/A	8.49	8.49
LNTH Lantheus	0.49	5.74	5.46
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
KYMR Kymera Therapeutics	N/A
LNTH Lantheus	99.06%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
KYMR Kymera Therapeutics	16.01%
LNTH Lantheus	2.00%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

KYMR, LNTH, RVMD, and BBIO Headlines

Recent News About These Companies

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24 at 10:05 PM | marketbeat.com

Revolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | Nasdaq

June 24 at 7:51 PM | nasdaq.com

Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24 at 3:50 PM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What Happened

June 24 at 12:28 PM | marketbeat.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24 at 7:19 AM | reuters.com

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 24 at 7:00 AM | globenewswire.com

Revolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...

June 23 at 1:22 PM | finanznachrichten.de

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23 at 9:00 AM | globenewswire.com

SG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 22 at 3:13 AM | marketbeat.com

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

June 19, 2025 | seekingalpha.com

GAMMA Investing LLC Purchases 20,696 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 18, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 13, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 1, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Analysts

June 1, 2025 | marketbeat.com

22,725 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Jefferies Financial Group Inc.

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Has $2.09 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 30, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Up 3.9% - Should You Buy?

May 29, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's Why

May 28, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 28, 2025 | marketbeat.com

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress

May 27, 2025 | investing.com

Nuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

KYMR, LNTH, RVMD, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$44.45 +2.28 (+5.41%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$44.21 -0.24 (-0.55%)

As of 04:05 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Kymera Therapeutics NASDAQ:KYMR

$47.14 +0.85 (+1.84%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$46.85 -0.29 (-0.62%)

As of 06/24/2025 07:37 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Lantheus NASDAQ:LNTH

$80.95 +0.14 (+0.17%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$79.31 -1.64 (-2.02%)

As of 04:05 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$40.03 -0.01 (-0.02%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$39.90 -0.13 (-0.31%)

As of 04:07 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time